strength shrug cyno shortfal
pre-announce revenu earlier month focu around
formal report expect view guidanc
set achiev level manag point concern
underscor recoveri breast health segment opportun
upgrad busi sens continu shift away
worri cynosur medic aesthet divis emphasi
solid result busi breast diagnost
seem us driver increas breast diagnost growth
multifactori sustain boost confid
continu regain credibl enjoy improv investor sentiment
breast recoveri help sever factor includ
ou expans strong servic focu recent acquisit
breast-conserv surgeri space product like smartcurv
paddl encourag upgrad cycl think invest
new offer continu drive revenu come quarter
conserv guidanc guidanc next quarter slightli light
top end revenu ep rang
non-gaap ep consensu sale
outlook narrow increas bottom end rang
maintain top end rang non-gaap ep
increas penni follow one-c beat quarter
bar meaning worsen fx landscap anticip
may beat rais throughout year
aesthet suffer competit fat reduct arena
fda headwind women health segment
valuat rate buy pt base
month adj ep estim risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
fiscal first quarter pre-announce total revenu
beat consensu estim out-performance came
strong breast health result healthi diagnost sale off-set
medic aesthet sale expect
 gross margin bp model sg spend
percentag revenu bp higher expect spend
bp lower project result oper margin bp
forecast tax rate line forecast
repurchas share expect overal adj ep beat
estim two cent
actualsbtig estimate variancebreast sale sale cytolog perinat molecular diagnost blood screen surgic sale novasur myosur sale sale revenu market admin incom incom gross bp sg spend bp spend bp ebit bp tax bpssourc btig estim compani filingsvari
though total revenu project chang much make sever
adjust forecast reflect busi trend manag
commentari go forward slightli reduc estim skelet
gyn surgic medic aesthet tweak forecast
diagnost sale well reflect strong molecular busi weak
cytology/perinat perform increas project breast health
sale outyear shift revenu intervent breast
solut segment breast imag segment forecast
total revenu toward top end guidanc rang
forecast revenu top end rang
 reduc share count guidanc model slightli lower
gross margin rest fiscal year tweak sg spend
nudg spend also revis forecast adjust
guidanc model adj ep ep
top guidanc rang project adj ep
ep top end guidanc rang lower share
count impact ep outyear
rate buy pt base month
adjust ep estim use multipl comp group reflect
compani slightli lower revenu growth also believ account
improv investor sentiment risk rate price target includ
cyno result adopt chang reimburs diagnost price
slowdown novasur competit success integr
cyno
revenu incom btig estim compani filingsnewold changentm entm eepsrevsdentsplyxraynot factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap
holog incom million except total y/i sell gener oper interest incom incom tax incom share net calendar loss oper btig estim compani report
holog revenu million except selenia dffm asp y/i selenia tomo asp y/i tomo instal y/i breast imag revenu system y/i breast imag y/i imag y/i breast y/i y/i breast y/i breast revenu y/i breast revenu y/i y/i y/i y/i diagnost y/i y/i y/i y/i gyn surgic y/i skelet y/i y/i y/i y/i aesthet revenu y/i y/i revenu y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
